A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia

Protocol No

JNJ-75276617ALE1001

Staff Member

Sameem Abedin

Phase

I/II

Summary

The purpose of this study is to see if a safe dose of JNJ-75276617 (the study drug) can be identified for treating participants with acute leukemia, including AML and ALL. Additional purposes include finding out if the study drug may be beneficial in treating acute leukemia, how long it stays in and acts on your body and how your body responds to it.

Objective

This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL